222 related articles for article (PubMed ID: 27234592)
1. Effects of vancomycin versus nafcillin in enhancing killing of methicillin-susceptible Staphylococcus aureus causing bacteremia by human cathelicidin LL-37.
Le J; Dam Q; Schweizer M; Thienphrapa W; Nizet V; Sakoulas G
Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1441-7. PubMed ID: 27234592
[TBL] [Abstract][Full Text] [Related]
2. Nafcillin enhances innate immune-mediated killing of methicillin-resistant Staphylococcus aureus.
Sakoulas G; Okumura CY; Thienphrapa W; Olson J; Nonejuie P; Dam Q; Dhand A; Pogliano J; Yeaman MR; Hensler ME; Bayer AS; Nizet V
J Mol Med (Berl); 2014 Feb; 92(2):139-49. PubMed ID: 24297496
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia.
Schweizer ML; Furuno JP; Harris AD; Johnson JK; Shardell MD; McGregor JC; Thom KA; Cosgrove SE; Sakoulas G; Perencevich EN
BMC Infect Dis; 2011 Oct; 11():279. PubMed ID: 22011388
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline.
Sakoulas G; Moise PA; Casapao AM; Nonejuie P; Olson J; Okumura CY; Rybak MJ; Kullar R; Dhand A; Rose WE; Goff DA; Bressler AM; Lee Y; Pogliano J; Johns S; Kaatz GW; Ebright JR; Nizet V
Clin Ther; 2014 Oct; 36(10):1317-33. PubMed ID: 25017183
[TBL] [Abstract][Full Text] [Related]
5. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.
LaPlante KL; Rybak MJ
Antimicrob Agents Chemother; 2004 Dec; 48(12):4665-72. PubMed ID: 15561842
[TBL] [Abstract][Full Text] [Related]
6. Human cathelicidin LL-37 resistance and increased daptomycin MIC in methicillin-resistant Staphylococcus aureus strain USA600 (ST45) are associated with increased mortality in a hospital setting.
Sakoulas G; Guram K; Reyes K; Nizet V; Zervos M
J Clin Microbiol; 2014 Jun; 52(6):2172-4. PubMed ID: 24648548
[TBL] [Abstract][Full Text] [Related]
7. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.
Pillai SK; Wennersten C; Venkataraman L; Eliopoulos GM; Moellering RC; Karchmer AW
Clin Infect Dis; 2009 Oct; 49(8):1169-74. PubMed ID: 19769538
[TBL] [Abstract][Full Text] [Related]
8. Increased resistance to cationic antimicrobial peptide LL-37 in methicillin-resistant strains of Staphylococcus aureus.
Ouhara K; Komatsuzawa H; Kawai T; Nishi H; Fujiwara T; Fujiue Y; Kuwabara M; Sayama K; Hashimoto K; Sugai M
J Antimicrob Chemother; 2008 Jun; 61(6):1266-9. PubMed ID: 18367458
[TBL] [Abstract][Full Text] [Related]
9. Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
Leonard SN
PLoS One; 2012; 7(7):e42103. PubMed ID: 22848719
[TBL] [Abstract][Full Text] [Related]
10. Nafcillin Augmentation of Daptomycin and Cathelicidin LL-37 Killing of Methicillin-resistant Staphylococcus epidermidis: Foundations of Successful Therapy of Endocarditis.
Catteau L; Iglesias YD; Tsunemoto H; Pogliano J; Van Bambeke F; Nizet V; Sakoulas G
Int J Antimicrob Agents; 2023 Jun; 61(6):106758. PubMed ID: 36775256
[TBL] [Abstract][Full Text] [Related]
11. Effects of sub-inhibitory concentrations of nafcillin, vancomycin, ciprofloxacin, and rifampin on biofilm formation of clinical methicillin-resistant
Park K-H; Kim D; Jung M; Kim DY; Lee Y-M; Lee MS; Hong K-W; Bae I-G; Hong SI; Cho O-H
Microbiol Spectr; 2024 Jun; 12(6):e0341223. PubMed ID: 38651875
[TBL] [Abstract][Full Text] [Related]
12. Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus.
Leonard SN; Supple ME; Gandhi RG; Patel MD
Antimicrob Agents Chemother; 2013 Jun; 57(6):2678-83. PubMed ID: 23545527
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
14. Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus.
Singh NB; Yim J; Jahanbakhsh S; Sakoulas G; Rybak MJ
Diagn Microbiol Infect Dis; 2018 Aug; 91(4):363-370. PubMed ID: 29807674
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of cefmenoxime, cefotaxime, latamoxef, cefazolin, nafcillin and vancomycin against 53 endocarditis and bacteremic strains of Staphylococcus aureus.
Dhawan VK; Maier MK; Nayyar M; Chuah SK; Thadepalli H
Chemotherapy; 1984; 30(5):328-30. PubMed ID: 6092007
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals.
Housman ST; Sutherland CA; Nicolau DP
Int J Antimicrob Agents; 2014 Sep; 44(3):235-41. PubMed ID: 25052866
[TBL] [Abstract][Full Text] [Related]
17. Vancomycin MICs and risk of complicated bacteremia by glycopeptide-susceptible Staphylococcus aureus.
Falcón R; Mateo E; Oltra R; Giménez E; Albert E; Torres I; Navarro D
Eur J Clin Microbiol Infect Dis; 2019 May; 38(5):903-912. PubMed ID: 30729396
[TBL] [Abstract][Full Text] [Related]
18. Reduced susceptibility to host-defense cationic peptides and daptomycin coemerge in methicillin-resistant Staphylococcus aureus from daptomycin-naive bacteremic patients.
Mishra NN; Bayer AS; Moise PA; Yeaman MR; Sakoulas G
J Infect Dis; 2012 Oct; 206(8):1160-7. PubMed ID: 22904338
[TBL] [Abstract][Full Text] [Related]
19. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
Mortin LI; Li T; Van Praagh AD; Zhang S; Zhang XX; Alder JD
Antimicrob Agents Chemother; 2007 May; 51(5):1787-94. PubMed ID: 17307984
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activity of oritavancin and other agents against methicillin-susceptible and methicillin-resistant Staphylococcus aureus.
Sweeney D; Shinabarger DL; Arhin FF; Belley A; Moeck G; Pillar CM
Diagn Microbiol Infect Dis; 2017 Feb; 87(2):121-128. PubMed ID: 27890418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
